This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HRC vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
PerkinElmer (PKI) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
PerkinElmer (PKI) introduces test for the detection of coronavirus after it receives EUA for the same.
OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
OPKO's BioReference Laboratories Widens COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
Abbott Launches Coronavirus Detection Test After FDA Gives EUA
by Zacks Equity Research
Abbott (ABT) launches test for the detection of coronavirus in human, after receiving the EUA.
Abbott (ABT) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $79.26 in the latest trading session, marking a -0.29% move from the prior day.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
Coronavirus Ails S&P 500 Index, MedTechs Bear the Brunt
by Urmimala Biswas
S&P 500 MedTech stocks pull the index further down on COVID-19 situation becoming grimmer.
HRC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
Neovasc (NVCN) Releases Update on Reducer and Tiara Products
by Zacks Equity Research
Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.
Abbott (ABT) Stock Moves -1.91%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $80.52 in the latest trading session, marking a -1.91% move from the prior day.
Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus
by Aparajita Dutta
The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Abbott's Alliance With Insulet to Fortify Diabetic Care Unit
by Zacks Equity Research
Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.
Insulet Partners With Dexcom for Automated Insulin Delivery
by Zacks Equity Research
This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More
by Urmimala Biswas
Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Breaking Q4 Earnings News
by Zacks Equity Research
Breaking Q4 Earnings News
Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB
by Mark Vickery
Certain weeks of the year are rife with important information for the stock market. This is not one of those weeks.
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
by Zacks Equity Research
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
Abbott (ABT) Meets Q4 Earnings Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?